Ask AI
ProCE Banner Activity

ELEVATE: Preliminary Safety and Efficacy of Elacestrant in Combination With Everolimus or Ribociclib in Patients With ER+/HER2- Locally Advanced or Metastatic Breast Cancer

Conference Coverage
Slideset

Elacestrant in combination with either everolimus or ribociclib demonstrated consistent safety profiles and meaningful efficacy in patients with ER+/HER2- advanced or metastatic BC after previous therapy with ET + CDK4/6 inhibition.

Released: June 04, 2025

Expiration: December 03, 2025

Share

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca, Daiichi Sankyo, Inc, Gilead Sciences, Inc., Lilly, Novartis Pharmaceuticals Corporation, and Stemline Therapeutics, Inc.

AstraZeneca

Daiichi Sankyo, Inc.

Gilead Sciences, Inc.

Lilly

Novartis Pharmaceuticals Corporation

Stemline Therapeutics, Inc.